Dihexa (5mg/capsule), 60 Capsules

Dihexa is studied for its proposed capacity to function as a potentiator of hepatocyte growth factor (HGF) at the MET receptor tyrosine kinase, rather than acting as a direct receptor agonist. Research models examine whether Dihexa binding stabilises HGF-MET receptor interactions or enhances receptor dimerisation, leading to amplified downstream signalling through pathways relevant to synaptic density and neuronal connectivity research.

The capsule format (5mg per capsule, 60 capsules) provides pre-measured, consistent dosing units suited to oral administration research protocols, while the powder format supports custom solution preparation for in vitro, parenteral, or variable-dose experimental designs. Researchers select format based on route of administration requirements and whether the protocol calls for fixed or variable dosing across experimental arms.

Primary hippocampal neuron cultures are used to study Dihexa's proposed effects on dendritic spine density and synaptic protein expression, typically measuring morphological changes via fluorescence microscopy and quantifying synaptic marker expression (such as PSD-95 or synaptophysin) relative to untreated controls. Rodent behavioural paradigms (such as Morris water maze or novel object recognition) provide complementary in vivo endpoints for studying cognitive function-related signalling research questions.